Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576509 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 743
- Enrollment target
- 20
- Study locations
NCT02576509: Completed Phase 3 study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
NCT02576509 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 743 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576509, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 743 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Primary Outcome
OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized participants. Participants who are alive will be censored at the last known alive dates. Based on Kaplan-Meier Estimates.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Sorafenib
Study Locations (20)
California
- Local Institution - 0020 - Los Angeles
- Local Institution - 0015 - San Francisco
- Local Institution - 0084 - San Francisco
Texas
- UT Southwestern Medical Center - Dallas
- Local Institution - 0017 - San Antonio
- Scott & White Memorial Hospital And Clinic - Temple
New York
- Local Institution - 0083 - New York
- Local Institution - 0093 - New York
Pennsylvania
- Local Institution - 0095 - Philadelphia
- Local Institution - 0019 - Philadelphia
Washington
- Local Institution - 0026 - Seattle
- University of Washington - Seattle Cancer Care Alliance - Seattle
Alabama
- Local Institution - 0066 - Birmingham
Illinois
- Local Institution - 0061 - Chicago
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 743 participants |
| Start Date | 2015-12-07 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 3 |
What the finished NCT02576509 record still lists
NCT02576509 is an interventional study that assigns participants to a tested intervention. The registered 743 participants enrollment target is mid-sized for trials with a published cap, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (195% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02576509 names 20 study sites across 13 states, led by California, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT02576509 about?
NCT02576509 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma". The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
What is the current status of trial NCT02576509?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 743 participants. The study started on 2015-12-07. Estimated completion is 2024-02-07.
What conditions does trial NCT02576509 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02576509?
The interventions under investigation include: Nivolumab (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT02576509?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576509 being conducted?
This trial has 20 study locations across Alabama, California, Illinois, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02576509's enrollment target sits among peer trials
743 14th of 145 higher than 132 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI